Acrofacial vitiligo secondary to PI3KCA inhibitor, alpelisib: case report
Alpelisib plus fulvestrant is a valid second or advanced line of treatment for patients with metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who harbor 10 inch an activating PIK3CA mutation.The well-known side effects of alpelisib are hyperglycemia, rash, and diarrhea.Herein, we report a case of a woman who developed diffuse